Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

sars-cov-2

Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

IPC Councilor Arnon Cohen shares his expert opinion on a study led by IPC Board Member Catherine Smith that described humoral and cellular immunity against SARS-CoV-2 spike glycoprotein in sixty-seven patients with psoriasis compared to fifteen healthy controls after the second dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech).

Read More

Expert Opinion: Psoriasis comprehensive review

The review is up-to-date and discusses the current knowledge and challenges in managing psoriasis during the SARS-CoV-2 pandemic and nicely points out future directions of psoriasis research by highlighting unresolved questions, new developments, and unmet medical needs.

Read More

Commentary: Sex differences in immune responses that underlie COVID-19 disease outcomes

Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK